Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features

PLoS ONE

Volumn 3, Issue 8, 2008, Pages

  Kool, Marcel ^a   Koster, Jan ^a   Bunt, Jens ^a   Hasselt, Nancy E ^a   Lakeman, Arjan ^a   van Sluis, Peter ^a   Troost, Dirk ^a   Schouten van Meeteren, Netteke ^a   Caron, Huib N ^a   Cloos, Jacqueline ^b   Mršić, Alan ^b   Ylstra, Bauke ^b   Grajkowska, Wieslawa ^c   Hartmann, Wolfgang ^d   Pietsch, Torsten ^d   Ellison, David ^e   Clifford, Steven C ^f   Versteeg, Rogier ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^d UNIVERSITY OF BONN   (Germany)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^f NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; BETA CATENIN; GENE PRODUCT; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR 1; GLUTAMATE RECEPTOR 2; GLUTAMATE RECEPTOR 8; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; NOTCH RECEPTOR; PLATELET DERIVED GROWTH FACTOR; PROTEIN DNM1; PROTEIN DNM3; PROTEIN DPYSL5; PROTEIN MAP2; PROTEIN MAST1; PROTEIN MPP3; PROTEIN NEOROD2; PROTEIN NEURL; PROTEIN NNAT; PROTEIN NPAS2; PROTEIN PATCHED 1; PROTEIN RTN1; PROTEIN RTN4R; PROTEIN VAMP4; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR OTX2; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; WNT PROTEIN; DNA; RNA;

ADOLESCENT; ADULT; ARTICLE; CANCER CLASSIFICATION; CHILD; CHROMOSOME 17; CHROMOSOME 6; CHROMOSOME 9Q; CHROMOSOME ABERRATION; CHROMOSOME LOSS; CLINICAL FEATURE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; METASTASIS; MONOSOMY; NERVE CELL DIFFERENTIATION; NUCLEOTIDE SEQUENCE; PHOTORECEPTOR; SIGNAL TRANSDUCTION; X CHROMOSOME INACTIVATION; CEREBELLUM TUMOR; CLASSIFICATION; GENETICS; GENOMICS; NUCLEIC ACID HYBRIDIZATION; PATHOLOGY; PHYSIOLOGY; PRESCHOOL CHILD;

ADOLESCENT; ADULT; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; MALE; MEDULLOBLASTOMA; NUCLEIC ACID HYBRIDIZATION; RNA, NEOPLASM; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 52449119078     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0003088     Document Type: Article

References (68)

1. Giangaspero F, Eberhart CG, Haapasalo H, Pietsch T, Wiestler OD, et al. (2007) Medulloblastoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. WHO classification of tumours of the central nervous system. Lyon: IARC Press. pp 132-140.
2. Bayani J, Zielenska M, Marrano P, Kwan Ng Y, Taylor MD, et al. (2000) Molecular cytogenetic analysis of medulloblastomas and supratentorial primitive neuroectodermal tumors by using conventional banding, comparative genomic, hybridization, and spectral karyotyping. J Neurosurg 93: 437-448.
3. Michiels EM, Weiss MM, Hoovers JM, Baak JP, Voute PA, et al. (2002) Genetic alterations in childhood medulloblastoma analyzed by comparative genomic hybridization. J Pediatr Hematol Oncol 24: 205-210.
4. Hui AB, Takano H, Lo KW, Kuo WL, Lam CN, et al. (2005) Identification of a novel homozygous deletion region at 6q23.1 in medulloblastomas using high-resolution array comparative genomic hybridization analysis. Clin Cancer Res 11: 4707-4716.
5. Pan E, Pellarin M, Holmes E, Smirnov I, Misra A, et al. (2005) Isochromosome 17q is a negative prognostic factor in poor-risk childhood medulloblastoma patients. Clin Cancer Res 11: 4733-4740.
6. McCabe MG, Ichimura K, Liu L, Plant K, Backlund LM, et al. (2006) High-resolution array-based comparative genomic hybridization of medulloblastomas and supratentorial primitive neuroectodermal tumors. J Neuropathol Exp Neurol 65: 549-561.
7. Rossi MR, Conroy J, McQuaid D, Nowak NJ, Rutka JT, et al. (2006) Array CGH analysis of pediatric medulloblastomas. Genes Chromosomes Cancer 45: 290-303.
8. Lamont JM, McManamy CS, Pearson AD, Clifford SC, Ellison DW (2004) Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res 10: 5482-5493.
9. Badiali M, Pession A, Basso G, Andreini L, Rigobello L, et al. (1991) N-myc and c-myc oncogenes amplification in medulloblastomas. Evidence of particularly aggressive behavior of a tumor with c-myc amplification. Tumori 77: 118-121.
10. Gilbertson RJ, Pearson AD, Perry RH, Jaros E, Kelly PJ (1995) Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma. Br J Cancer 71: 473-477.
11. Herms J, Neidt I, Luscher B, Sommer A, Schurmann P, et al. (2000) C-MYC expression in medulloblastoma and its prognostic value. Int J Cancer 89: 395-402.
12. Grötzer MA, Janss AJ, Phillips PC, Trojanowski JQ (2000) Neurotrophin receptor TrkC predicts good clinical outcome in medulloblastoma and other primitive neuroectodermal brain tumors. Klin Padiatr 212: 196-199.
13. Grötzer MA, Hogarty MD, Janss AJ, Liu X, Zhao H, et al. (2001) MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res 7: 2425-2433.
14. Gilbertson R, Wickramasinghe C, Hernan R, Balaji V, Hunt D, et al. (2001) Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer 85: 705-712.
15. Eberhart CG, Kepner JL, Goldthwaite PT, Kun LE, Duffner PK, et al. (2002) Histopathologic grading of medulloblastomas: a pediatric oncology group study. Cancer 94: 552-560.
16. Aldosari N, Bigner SH, Burger PC, Becker L, Kepner JL, et al. (2002) MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. Arch Pathol Lab Med 126: 540-544.
17. Ellison DW, Onilude OE, Lindsey JC, Lusher ME, Weston CL, et al. (2005) beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol 23: 7951-7957.
18. Rutkowski S, von Bueren A, von Hoff K, Hartmann W, Shalaby T, et al. (2007) Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT'91. Clin Cancer Res 13: 2651-2657.
19. Pietsch T, Waha A, Koch A, Kraus J, Albrecht S, et al. (1997) Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched. Cancer Res 57: 2085-2088.
20. Huang H, Mahler-Araujo BM, Sankila A, Chimelli L, Yonekawa Y, et al. (2000) APC mutations in sporadic medulloblastomas. Am J Pathol 156: 433-437.
21. Dahmen RP, Koch A, Denkhaus D, Tonn JC, Sorensen N, et al. (2001) Deletions of AXIN1, a component of the WNT/wingless pathway, in sporadic medulloblastomas. Cancer Res 61: 7039-7043.
22. Koch A, Waha A, Tonn JC, Sorensen N, Berthold F, et al. (2001) Somatic mutations of WNT/wingless signaling pathway components in primitive neuroectodermal tumors. Int J Cancer 93: 445-449.
23. Taylor MD, Liu L, Raffel C, Hui CC, Mainprize TG, et al. (2002) Mutations in SUFU predispose to medulloblastoma. Nat Genet 31: 306-310.
24. Michiels EMC, Oussoren E, van Groenigen M, Pauws E, Bossuyt PMM, et al. (1999) Genes differentially expressed in medulloblastoma and fetal brain. Physiol Genomics 1: 83-91.
25. Boon K, Edwards JB, Siu IM, Olschner D, Eberhart CG, et al. (2003) Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes. Oncogene 22: 7687-7694.
26. Boon K, Eberhart CG, Riggins GJ (2005) Genomic amplification of orthodenticle homologue 2 in medulloblastomas. Cancer Res 65: 703-707.
27. Di C, Liao S, Adamson DC, Parrett TJ, Broderick DK, et al. (2005) Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. Cancer Res 65: 919-924.
28. de Haas T, Oussoren E, Grajkowska W, Perek-Polnik M, Popovic M, et al. (2006) OTX1 and OTX2 expression correlates with the clinicopathologic classification of medulloblastomas. J Neuropathol Exp Neurol 65: 1-11.
29. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, et al. (2002) Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415: 436-442.
30. Thompson MC, Fuller C, Hogg TL, Dalton J, Finkelstein D, et al. (2006) Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 24: 1924-1931.
31. Saeed AI, Sharov V, White J, Li J, Liang W, et al. (2003) TM4: a free, open-source system for microarray data management and analysis. Biotechniques 34: 374-378.
32. Kim SY, Volsky DJ (2005) PAGE: parametric analysis of gene set enrichment. BMC Bioinformatics 6: 144.
33. van den IJssel P, Tijssen M, Chin SF, Eijk P, Carvalho B, et al. (2005) Human and mouse oligonucleotide-based array CGH. Nucleic Acids Res 33: e192.
34. van de Wiel MA, Kim KI, Vosse SJ, van Wieringen WN, Wilting SM, et al. (2007) CGHcall: calling aberrations for array CGH tumor profiles. Bioinformatics 23: 892-894.
35. Zurawel RH, Chiappa SA, Allen C, Raffel C (1998) Sporadic medulloblastomas contain oncogenic beta-catenin mutations. Cancer Res 58: 896-899.
36. Eberhart CG, Tihan T, Burger PC (2000) Nuclear localization and mutation of beta-catenin in medulloblastomas. J Neuropathol Exp Neurol 59: 333-337.
37. Yokota N, Nishizawa S, Ohta S, Date H, Sugimura H, et al. (2002) Role of Wnt pathway in medulloblastoma oncogenesis. Int J Cancer 101: 198-201.
38. Clifford SC, Lusher ME, Lindsey JC, Langdon JA, Gilbertson BJ, et al. (2006) Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle 5: 2666-2670.
39. Raffel C, Jenkins RB, Frederick L, Hebrink D, Alderete B, et al. (1997) Sporadic medulloblastomas contain PTCH mutations. Cancer Res 57: 842-845.
40. Wolter M, Reifenberger J, Sommer C, Ruzicka T, Reifenberger G (1997) Mutations in the human homologue of the Drosophila segment polarity gene patched (PTCH) in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 57: 2581-2585.
41. Yuki D, Lin YM, Fujii Y, Nakamura Y, Furukawa Y (2004) Isolation of LEM domain-containing 1, a novel testis-specific gene expressed in colorectal cancers. Oncol Rep 12: 275-280.
42. Iolascon A, Lania A, Badiali M, Pession A, Saglio G, et al. (1991) Analysis of N-ras gene mutations in medulloblastomas by polymerase chain reaction and oligonucleotide probes in formalin-fixed, paraffin-embedded tissues. Med Pediatr Oncol 19: 240-245.
43. Gilbertson RJ, Langdon JA, Hollander A, Hernan R, Hogg TL, et al. (2006) Mutational analysis of PDGFR-RAS/MAPK pathway activation in childhood medulloblastoma. Eur J Cancer 42: 646-649.
44. Strother DR, Pollack IF, Fisher PA, Hunter JV, Woo SY, et al. (2002) Tumors of the central nervous system. In: Pizzo AP, Poplack DG, eds. Principles and Practice of Pediatric Oncology. 3rd edition ed. Philadelphia: Lippincott Williams & Wilkins.
45. Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, et al. (2006) Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 7: 813-820.
46. MacDonald TJ, Brown KM, LaFleur B, Peterson K, Lawlor C, et al. (2001) Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nature Genet 29: 143-152.
47. Gilbertson RJ, Clifford SC (2003) PDGFRB is overexpressed in metastatic medulloblastoma. Nature Genet 35: 197-198.
48. Giangaspero F, Perilongo G, Fondelli MP, Brisigotti M, Carollo C, et al. (1999) Medulloblastoma with extensive nodularity: a variant with favorable prognosis. J Neurosurg 91: 971-977.
49. Rutkowski S, Bode U, Deinlein F, Ottensmeier H, Warmuth-Metz M, et al. (2005) Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 352: 978-986.
50. McManamy CS, Pears J, Weston CL, Hanzely Z, Ironside JW, et al. (2007) Nodule formation and desmoplasia in medulloblastomas-defining the nodular/desmoplastic variant and its biological behavior. Brain Pathol 17: 151-164.
51. Korf HW, Gotz W, Herken R, Theuring F, Gruss P, et al. (1990) S-antigen and rod-opsin immunoreactions in midline brain neoplasms of transgenic mice: similarities to pineal cell tumors and certain medulloblastomas in man. J Neuropathol Exp Neurol 49: 424-437.
52. Korf HW, Czerwionka M, Reiner J, Schachenmayr W, Schalken JJ, et al. (1987) Immunocytochemical evidence of molecular photoreceptor markers in cerebellar medulloblastomas. Cancer 60: 1763-1766.
53. Bonnin JM, Perentes E (1988) Retinal S-antigen immunoreactivity in medulloblastomas. Acta Neuropathol 76: 204-207.
54. Czerwionka M, Korf HW, Hoffmann O, Busch H, Schachenmayr W (1989) Differentiation in medulloblastomas: correlation between the immunocytochemical demonstration of photoreceptor markers (S-antigen, rod-opsin) and the survival rate in 66 patients. Acta Neuropathol 78: 629-636.
55. Kramm CM, Korf HW, Czerwionka M, Schachenmayr W, de Grip WJ (1991) Photoreceptor differentiation in cerebellar medulloblastoma: evidence for a functional photopigment and authentic S-antigen (arrestin). Acta Neuropathol 81: 296-302.
56. Korf HW, Korf B, Schachenmayr W, Chader GJ, Wiggert B (1992) Immunocytochemical demonstration of interphotoreceptor retinoid-binding protein in cerebellar medulloblastoma. Acta Neuropathol 83: 482-487.
57. Jaffey PB, To GT, Xu HJ, Hu SX, Benedict WF, et al. (1995) Retinoblastoma-like phenotype expressed in medulloblastomas. J Neuropathol Exp Neurol 54: 664-672.
58. Donoso LA, Felberg NT, Augsburger JJ, Shields JA (1985) Retinal S-antigen and retinoblastoma: a monoclonal antibody and flow cytometric study. Invest Opthalmol Vis Sci 26: 568-571.
59. Donoso LA, Hamm H, Dietzschold B, Augsburger JJ, Shield JA, et al. (1986) Rhodopsin and retinoblastoma. A monoclonal antibody histopathologic study. Arch Opthalmol 109: 111-113.
60. Korf HW, Klein DC, Zigler JS, Gery I, Schachenmayr W (1986) S-antigen like immunoreactivity in a human pineocytoma. Acta Neuropathol 69: 165-167.
61. Perentes E, Rubinstein LJ, Herman MM, Donoso LA (1986) S-antigen immumoreactivity in human pineal glands and pineal parenchymal tumors. A monoclonla antibody study. Acta Neuropathol 71: 224-227.
62. Marcus DM, Brooks SE, Leff G, McCormick R, Thompson T, et al. (1998) Trilateral retinoblastoma: insights into histogenesis and management. Surv Ophthalmol 43: 59-70.
63. Elias WJ, Lopes MB, Golden WL, Jane JA Sr, Gonzalez-Fernandez F (2001) Trilateral retinoblastoma variant indicative of the relevance of the retinoblastoma tumor-suppressor pathway to medulloblastomas in humans. J Neurosurg 95: 871-878.
64. Marino S, Vooijs M, van der Gulden H, Jonkers J, Berns A (2000) Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev 14: 994-1004.
65. Theuring F, Götz W, Balling R, Korf H-W, Schulze F, et al. (1990) Tumorigenesis and eye abnormalities in transgenic mice expressing MSV-SV 40 large T-antigen. Oncogene 5: 225-232.
66. Felsani A, Mileo AM, Paggi MG (2006) Retinoblastoma family proteins as key targets of the small DNA virus oncoproteins. Oncogene 25: 5277-5285.
67. Olson MV, Johnson DG, Jiang H, Xu J, Alonso MM, et al. (2007) Transgenic E2F1 expression in the mouse brain induces a human-like bimodal pattern of tumors. Cancer Res 67: 4005-4009.
68. Pietsch T, Taylor MD, Rutka JT (2004) Molecular pathogenesis of childhood brain tumors. J Neurooncol 70: 203-215.